Informing the design of disease modifying trials for Parkinson's disease - A Delphi study

被引：0
|
作者：
Zeissler, M.
Windle, R.
Raphael, K.
Rafaloff, G.
McFarthing, K.
Matthews, H.
Carroll, C.
机构：
来源：
MOVEMENT DISORDERS | 2021年 / 36卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
452
引用
收藏
页码：S200 / S200
页数：1
相关论文
共 50 条
  • [1] Using a Delphi process to inform the design of disease modifying trials in Parkinson's disease
    Zeissler, M.
    Windle, R.
    McFarthing, K.
    Raphael, K.
    Rafaloff, G.
    Carroll, C.
    MOVEMENT DISORDERS, 2020, 35 : S433 - S433
  • [2] An International Multi-Stakeholder Delphi Survey Study on the Design of Disease Modifying Parkinson's Disease Trials
    Zeissler, Marie-Louise
    McFarthing, Kevin
    Raphael, Karen G.
    Rafaloff, Gary
    Windle, Richard
    Carroll, Camille B.
    JOURNAL OF PARKINSONS DISEASE, 2023, 13 (08) : 1343 - 1356
  • [3] Considerations for trials of disease modifying treatments in Parkinson disease
    Ahlskog, J. Eric
    NEUROLOGY, 2020, 94 (11) : 467 - 468
  • [4] Advantages and Challenges of Platform Trials for Disease Modifying Therapies in Parkinson's Disease
    Fabbri, Margherita
    Rascol, Olivier
    Foltynie, Tom
    Carroll, Camille
    Postuma, Ronald B.
    Porcher, Raphael
    Corvol, Jean Christophe
    MOVEMENT DISORDERS, 2024, 39 (09) : 1468 - 1477
  • [5] A new approach to disease-modifying drug trials in Parkinson's disease
    Barker, Roger A.
    Stacy, Mark
    Brundin, Patrik
    JOURNAL OF CLINICAL INVESTIGATION, 2013, 123 (06): : 2364 - 2365
  • [6] How can we improve the design and endpoints of symptomatic and disease modifying clinical trials in Parkinson's disease?
    Clarke, C. E.
    BASAL GANGLIA, 2012, 2 (04) : 201 - 204
  • [7] Impacts on study design when implementing digital measures in Parkinson's disease-modifying therapy trials
    Lavine, Jennie S.
    Scotina, Anthony D.
    Haney, Seth
    Bakker, Jessie P.
    Izmailova, Elena S.
    Omberg, Larsson
    FRONTIERS IN DIGITAL HEALTH, 2024, 6
  • [8] Optimum Design of Disease-Modifying Trials on Alzheimer's Disease
    Xiong, Chengjie
    Luo, Jingqin
    Gao, Feng
    Chen, Ling
    Yan, Yan
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2012, 4 (03): : 216 - 227
  • [9] Investigating trial design variability in trials of disease-modifying therapies in Parkinson's disease: a scoping review protocol
    Zeissler, Marie-Louise
    Boey, Timothy
    Chapman, Danny
    Rafaloff, Gary
    Dominey, Thea
    Raphael, Karen G.
    Buff, Susan
    Pai, Hari Venkatesh
    King, Emma
    Sharpe, Paul
    O'Brien, Fintan
    Carroll, Camille B.
    BMJ OPEN, 2023, 13 (12):
  • [10] Disease modifying agents in Parkinson's disease?
    Schapira, A. H. V.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2009, 285 : S46 - S46
12345